On Invalid Date, Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported Q2 2022 earnings per share (EPS) of -$0.29, up 52.46% year over year. Total Kiniksa Pharmaceuticals earnings for the quarter were -$19.98 million. In the same quarter last year, Kiniksa Pharmaceuticals's earnings per share (EPS) was -$0.61.
As of Q3 2022, Kiniksa Pharmaceuticals's earnings has grown year over year. Kiniksa Pharmaceuticals's earnings in the past year totalled -$112.07 million.
What is KNSA's earnings date?
Kiniksa Pharmaceuticals's earnings date is Invalid Date. Add KNSA to your watchlist to be reminded of KNSA's next earnings announcement.
What was KNSA's revenue last quarter?
On Invalid Date, Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported Q2 2022 revenue of $26.97 million up 250.1% year over year. In the same quarter last year, Kiniksa Pharmaceuticals's revenue was $7.70 million.
What was KNSA's revenue growth in the past year?
As of Q3 2022, Kiniksa Pharmaceuticals's revenue has grown 1,068.24% year over year. This is 52.48 percentage points lower than the US Biotechnology industry revenue growth rate of 1,120.72%. Kiniksa Pharmaceuticals's revenue in the past year totalled $90.00 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.